Cost-effectiveness of early rhythm control vs. usual care in atrial fibrillation care: an analysis based on data from the EAST-AFNET 4 trial.

Sophie Gottschalk,Shinwan Kany,Hans-Helmut König,Harry Jgm Crijns,Panos Vardas,A John Camm,Karl Wegscheider,Andreas Metzner,Andreas Rillig,Paulus Kirchhof,Judith Dams

Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology（2023）

引用 5|浏览24

暂无评分

摘要

From a German healthcare payer's perspective, health benefits of ERC may come at reasonable costs as indicated by the ICER point estimates. Taking statistical uncertainty into account, cost-effectiveness of ERC is highly probable at a willingness-to-pay value of ≥€55 000 per additional life year or year without a primary outcome. Future studies examining the cost-effectiveness of ERC in other countries, subgroups with higher benefit from rhythm control therapy, or cost-effectiveness of different modes of ERC are warranted.

查看译文

关键词

Atrial fibrillation,Cost-effectiveness,Early rhythm control

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要